Background
==========

The urgency to develop sustainable fossil fuel alternatives is driven by rapidly increasing global consumption, irreversibly diminishing reserves, unpredictable geopolitical factors, fluctuating price of crude oil, growing concerns about national energy security, and serious environmental concerns surrounding immense greenhouse gas emissions mainly resulting from combustion of fossil fuels \[[@B1]-[@B3]\]. Biofuels produced from biological resources represent a compelling alternative to fossil fuels because they are renewable and more environmentally friendly \[[@B4]-[@B7]\]. Among various biofuels, bioethanol and biodiesel are dominating the current global market. However, it is widely accepted that the ideal biofuels are bio-hydrocarbons, especially the medium- to long-chain fatty alkanes or alkenes, because they highly mimic the chemical composition and physical characteristics of petroleum-based fuels \[[@B8]-[@B10]\]. Thus, the biosynthetic pathways for aliphatic hydrocarbons from diverse organisms have been attracting great attentions in recent years \[[@B11]-[@B13]\]. Particularly, the scalable and cost-effective microbial biosynthesis of fatty alkanes or alkenes is considered as one of the most promising ways to produce 'drop-in compatible' biofuels \[[@B5],[@B8]\].

To date, four microbial biosynthetic pathways that convert free fatty acids or fatty acid thioesters into bio-hydrocarbons have been identified, including the cyanobacterial pathways consisting of an acyl-acyl carrier protein (acyl-ACP) reductase and an aldehyde decarbonylase, which together convert fatty acyl-ACPs into alkanes \[[@B14]\]; a three-gene cluster responsible for generating alkenes with internal double bonds through the head-to-head condensation of two fatty acyl-coenzyme A (acyl-CoA) molecules in *Micrococcus luteus*\[[@B15]\]; a unique P450 decarboxylase OleT~JE~ from *Jeotgalicoccus* sp. ATCC 8456, which directly decarboxylates long-chain fatty acids to form *α*-olefins in presence of H~2~O~2~\[[@B16],[@B17]\]; and a type I polyketide synthase from *Synechococcus* sp. PCC 7002 \[[@B18],[@B19]\], which is capable of transforming fatty acyl-ACPs into *α*-olefins via sequential polyketide synthase chain elongation, keto reduction, sulfonation mediated by its sulfotransferase domain, and the coupled hydrolysis and decarboxylation catalyzed by the thioesterase domain.

Among these pathways, the single-step decarboxylation of fatty acids catalyzed by OleT~JE~ P450 enzyme \[[@B16]\] apparently represents the simplest one. Moreover, it directly uses free fatty acids instead of fatty acid thioesters as substrates, which is believed to be advantageous for metabolic engineering because fatty acids are more abundant and their abundance and composition can be well manipulated in *E. coli*\[[@B20]-[@B22]\], one of the most developed microbial cell factories. Thus, this P450 fatty acid decarboxylative machinery may hold great potential to be engineered into a biological *α*-alkene-producing system. Notably, in addition to being biofuel molecules, *α*-alkenes are also used broadly for making lubricants, polymers and detergents \[[@B17],[@B23],[@B24]\].

The superfamily of cytochrome P450 enzymes (CYPs) are considered among the most versatile biocatalysts in nature \[[@B25]\]. Typically, P450 enzymes employ one or more redox partner proteins to transfer two electrons from NAD(P)H to the heme iron reactive center for dioxygen activation, and then insert one atom of O~2~ into their substrates \[[@B25]-[@B27]\]. Therefore, these oxidative biocatalysts are often termed as P450 monooxygenases. However, the CYP152 family members such as P450~SPα~\[[@B28]\], P450~BSβ~\[[@B29]\] and OleT~JE~\[[@B16]\] have been identified to exclusively use H~2~O~2~ as the sole electron and oxygen donor, and are thus classified into a unique P450 peroxygenase category.

Practically, the peroxygenase activity of P450 enzymes is often treated as an advantageous feature because H~2~O~2~ is much cheaper than NADPH and redox proteins in many P450 applications such as biocatalysts for *in vitro* synthetic reactions and enzyme additives in laundry detergents \[[@B30],[@B31]\]. However, the large-scale production of low-cost *α*-alkene biofuels by OleT~JE~ P450 decarboxylase cannot rely on the H~2~O~2~-dependent enzymatic system because the use of large amounts of peroxide is cost prohibitive, and high concentration of H~2~O~2~ can quickly deactivate biocatalysts \[[@B32]\].

Therefore, the H~2~O~2~-independent activity of OleT~JE~, if it exists, is preferred for cost-effective microbial production of *α*-alkenes. In the present study, we demonstrated such activity for the first time. Through engineering a self-sufficient version of OleT~JE~ by fusing it to the *Rhodococcus* fusion reductase (RhFRED) domain from *Rhodococcus* sp. NCIMB 9784 \[[@B33]\], the catalytic activity of the resultant fusion P450 enzyme can be solely driven by NADPH. We also found that *E. coli* flavodoxin (Fld) and flavodoxin reductase (FdR) are capable of supporting OleT~JE~ activity as well. Guided by these new findings, our initial metabolic engineering efforts based on the H~2~O~2~-independent decarboxylation of fatty acids by OleT~JE~*in vivo* led to a group of *α*-alkene overproducers with the best one producing 97.6 mg·l^-1^ total *α*-alkenes.

Results
=======

*In vitro* fatty acid decarboxylation by OleT~JE~ and OleT~JE~-RhFRED
---------------------------------------------------------------------

The unusual activity of the first P450 fatty acid decarboxylase OleT~JE~ was determined by reconstituted *in vitro* reactions \[[@B16]\]. Specifically, OleT~JE~ was able to decarboxylate stearic acid and palmitic acid to generate 1-heptadecene and 1-pentadecene, respectively, in the presence of H~2~O~2~ (Figure [1](#F1){ref-type="fig"}A). It also catalyzed the *α*- and *β*-hydroxylation of fatty acids as side reactions. Using the purified P450 enzymes (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1 and Additional file [2](#S2){ref-type="supplementary-material"}: Figure S2), we first confirmed these three types of activity of OleT~JE~ using myristic acid (C~14~) as substrate. Consistent with the previous report \[[@B16]\], fatty acid decarboxylation was the dominant reaction, while the *α*- and *β*-hydroxymyristic acid only accounted for 0.2% and 6.1% of total products, respectively (Figure [1](#F1){ref-type="fig"}B).

![**Decarboxylation and hydroxylation reactions catalyzed by OleT**~**JE.**~**(A)** The decarboxylation and hydroxylation of fatty acids (C~12~ to C~20~) catalyzed by OleT~JE~. **(B)** Product distribution of the decarboxylation and hydroxylation reactions catalyzed by purified OleT~JE~ and OleT~JE~-RhFRED, respectively. Myristic acid was used as substrate. 1-TE, 1-tridecene; *α*-OH MA, *α*-hydroxy myristic acid; *β*-OH MA, *β*-hydroxy myristic acid.](1754-6834-7-28-1){#F1}

According to previous amino acid sequence analysis, OleT~JE~ was assigned to the CYP152 family, with the well-studied P450~BSβ~\[[@B29],[@B34],[@B35]\] from *Bacillus subtilis* and P450~SPα~\[[@B28],[@B36]\] from *Sphingomonas paucimobilis* as family members. Essentially, this family of P450 enzymes utilizes H~2~O~2~ as the sole electron and oxygen donor to oxidize their substrates, in contrast to most other P450 monooxygenases, whose catalytic activity depends on dioxygen, NAD(P)H and redox partner protein(s) \[[@B37]\]. Thus, these P450 enzymes are functionally referred to as peroxygenases \[[@B38]\]. Indeed, it was reported that P450 reductase systems such as ferredoxin and ferredoxin reductase did not support the activity of P450~BSβ~ and P450~SPα~\[[@B36],[@B39]\]. This is consistent with the substitution of Pro^246^ and Arg^245^ (numbering in OleT~JE~) in CYP152 peroxygenases for the highly conserved threonine and an acidic residue (for example, Glu or Asp) in most P450 monooxygenases (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3), which are involved in a specific H-bond network responsible for delivery of protons during the P450 catalytic cycle \[[@B34],[@B40]\].

However, in the study of another CYP152-member P450~CLA~, from the anaerobic microorganism *Clostridium acetobutylicum*\[[@B41]\], it was demonstrated that both P450~CLA~ and P450~BSβ~ functioned when provided with O~2~, NADPH and flavodoxin/flavodoxin reductase from *E. coli* or the diflavin reductase domain of P450~BM3~ from *Bacillus megaterium*, suggesting an alternative monooxygenase-like mechanism of these P450 peroxygenases.

To investigate whether OleT~JE~ peroxygenase can also function as a monooxygenase like P450~CLA~ and P450~BSβ~, the RhFRED reductase domain from *Rhodococcus* sp. NCIMB 9784 \[[@B33]\] was fused to the C-terminus of OleT~JE~. In the presence of the electron donor NADPH, the fusion protein OleT~JE~-RhFRED successfully converted lauric acid (C~12~) into 1-undecene with the conversion ratio of 51.1 ±0.3%, approximately half that of OleT~JE~ plus H~2~O~2~ (93.0 ±4.3% conversion; Figure [2](#F2){ref-type="fig"}). Notably, the product distribution (decarboxylation *versus* hydroxylation) of the OleT~JE~-RhFRED catalyzed reaction was similar to that of the OleT~JE~ reaction (Figure [1](#F1){ref-type="fig"}B), indicating the fused reductase domain has no significant impact on the catalytic mechanism of P450 domain. As control, OleT~JE~ cannot directly use NADPH as electron donor. OleT~JE~-RhFRED was not active by itself. Interestingly, OleT~JE~-RhFRED retained its ability to use H~2~O~2~ as a cofactor, but there was not a significant additive effect between NADPH and H~2~O~2~ for supporting the activity of OleT~JE~-RhFRED (Figure [2](#F2){ref-type="fig"}).

![**Gas chromatography-mass spectroscopy analysis of decarboxylation reactions (10 min) catalyzed by OleT**~**JE**~**or OleT**~**JE**~**-RhFRED under different reaction systems. (A)** OleT~JE~ + H~2~O~2~; **(B)** OleT~JE~ + NADPH; **(C)** OleT~JE~-RhFRED + NADPH; **(D)** OleT~JE~-RhFRED + H~2~O~2;~**(E)** OleT~JE~-RhFRED + NADPH + H~2~O~2;~**(F)** OleT~JE~-RhFRED in absence of NADPH; **(G)** authentic standards of 1-undecene (U) lauric acid (LA) and heptadecanoic acid (IS: internal standard).](1754-6834-7-28-2){#F2}

To prevent the spontaneous generation of H~2~O~2~ during the OleT~JE~-RhFRED reaction, which could complicate interpretation of the results, dithiothreitol (DTT: the reducing agent often used in the storage and reaction buffer of P450 proteins) was omitted from all buffers used during protein purification, storage and reaction because it has previously been reported that DTT, dioxygen and the heme iron center of P450 can react to generate H~2~O~2~\[[@B16],[@B42]\]. To further exclude the possibility that H~2~O~2~ could be produced from the peroxide shunt pathway during the monooxygenase catalytic cycle \[[@B27]\], bovine liver catalase that is able to efficiently eliminate H~2~O~2~ was added to the fatty acid decarboxylation reactions (in the DTT-free buffer) catalyzed by OleT~JE~ and OleT~JE~-RhFRED. In the OleT~JE~ plus H~2~O~2~ system, pre-addition of catalase completely abolished the reaction (Figure [3](#F3){ref-type="fig"}). By contrast, in the OleT~JE~-RhFRED plus NADPH reaction, pre-added catalase did not significantly change (indeed, it slightly improved) the conversion of myristic acid to 1-tridecene (Figure [3](#F3){ref-type="fig"}). This clearly indicates that the decarboxylation activity of OleT~JE~-RhFRED can be solely supported by NADPH.

![**Effects of catalase on the*in vitro*decarboxylation activity of three OleT**~**JE**~**(1 μM) reaction systems. Systems comprised OleT**~**JE**~**plus H**~**2**~**O**~**2**~**, OleT**~**JE**~**-RhFRED plus NADPH, and OleT**~**JE**~**plus flavodoxin and flavodoxin reductase plus NADPH.** The percentage conversion of myristic acid is shown beside each bar.](1754-6834-7-28-3){#F3}

Substrate specificity of OleT~JE~ and OleT~JE~-RhFRED
-----------------------------------------------------

The substrate preference of OleT~JE~ and OleT~JE~-RhFRED provides useful information to help understand the *in vivo* behavior of these fatty acid decarboxylases and to guide the metabolic engineering of fatty acid biosynthesis. Thus, we determined their substrate specificity (Figure [4](#F4){ref-type="fig"}) using a number of straight-chain saturated fatty acids with even-numbered chain length ranging from C~8~ to C~20~. In the case of OleT~JE~ (Figure [4](#F4){ref-type="fig"}A), myristic acid (C~14~) turned out to be the best substrate for olefin production among the tested fatty acids with the conversion ratio of 97.0 ± 2.8%. Lauric acid (C~12~) and palmitic acid (C~16~) were sub-optimal. OleT~JE~ was only able to convert a minority of stearic acid (C~18~) and arachidic acid (C~20~), but could not decarboxylate capric acid (C~10~) or caprylic acid (C~8~).

![**Substrate preference spectrum of (A) OleT**~**JE**~**and (B) OleT**~**JE**~**-RhFRED.** The substrate preference was determined by calculating the percentage conversion of each fatty acid substrate into corresponding *α*-alkene product. In these assays, 0.2 μM enzymes were used.](1754-6834-7-28-4){#F4}

In comparison, the substrate preference spectrum of OleT~JE~-RhFRED slightly shifted toward shorter fatty acids (Figure [4](#F4){ref-type="fig"}B), which suggests that the P450-reductase interaction might induce small conformational change of the OleT~JE~ active site. Specifically, OleT~JE~-RhFRED showed the highest activity against lauric acid (83.8 ±0.1% conversion), but was inactive toward arachidic acid. Similar to OleT~JE~, OleT~JE~-RhFRED could not decarboxylate capric acid or caprylic acid. It is also worth noting that the system of OleT~JE~-RhFRED plus NADPH plus O~2~ was less active than OleT~JE~ plus H~2~O~2~ when reacting with most tested fatty acids except for lauric acid, suggesting OleT~JE~ might have evolved to become a better peroxygenase than a monooxygenase.

*In vivo* production of *α*-alkenes in *Escherichia coli*
---------------------------------------------------------

Motivated by the efficient *in vitro* conversion of free fatty acids (C~n~) to corresponding *α*-alkenes (C~n-1~) by two related but mechanistically distinct decarboxylation systems including OleT~JE~ plus H~2~O~2~ and OleT~JE~-RhFRED plus NADPH plus O~2~, we sought to engineer hydrocarbon-producing strains of *E. coli*. To guarantee sufficient substrate supply of free fatty acids for OleT~JE~ P450 decarboxylase, two previously engineered fatty acid-overproducing strains including XL100 (BL21:*ΔfadD*) and XL100/(pMSD8 + pMSD15) \[[@B43]\] were used as hosts for the decarboxylases. Transformation of these two strains with pET28b-*oleT*~*JE*~ or pET28b-*oleT*~*JE*~-*RhFRED* resulted in YL5 (XL100 with pET28b-*oleT*~*JE*~), YL6 (XL100 with pET28b-*oleT*~*JE*~-*RhFRED*), YL7 (XL100 with pET28b-*oleT*~*JE*~, pMSD8 and pMSD15), and YL8 (XL100 with pET28b-*oleT*~*JE*~-*RhFRED*, pMSD8 and pMSD15) (Table [1](#T1){ref-type="table"}).

###### 

Strains and plasmids used in this study

  **Strain or plasmid**            **Relevant characteristics**                                                                                                     **Source or reference**
  -------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------
  *E. coli* strains                                                                                                                                                  
  BL21(DE3)                        F^-^*ompT gal dcm lon hsdSB* (r~B~^-^ m~B~^-^) λ(DE3)                                                                            Novagen
  DH5α                             F^-^ ξ80*lacZ*ΔM15 Δ (Δl*acZYA*-*argF*) U169 *recA*1 *endA*1 *hsdR*17 (rk^-^, mk^+^) *phoA supE*44 *thi-*1 *gyrA96 relA1 λ*^-^   Invitrogen
  XL100                            BL21: Δ*fadD*^a^                                                                                                                 \[[@B43]\]
  YL1                              BL21(DE3) with pET28b-*oleT*~*JE*~                                                                                               This study
  YL2                              BL21(DE3) with pET28b-*oleT*~*JE*~-*RhFRED*                                                                                      This study
  YL3                              BL21(DE3) with pACYCDuet-*fdR*                                                                                                   This study
  YL4                              BL21(DE3) with pCDEDuet-*fld*                                                                                                    This study
  YL5                              XL100 with pET28b-*oleT*~*JE*~                                                                                                   This study
  YL6                              XL100 with pET28b-*oleT*~*JE*~-*RhFRED*                                                                                          This study
  YL7                              XL100 with pET28b-*oleT*~*JE*~, pMSD8^b^, pMSD15^c^                                                                              This study
  YL8                              XL100 with pET28b-*oleT*~*JE*~-*RhFRED*, pMSD8, pMSD15                                                                           This study
  *Jeotgalicoccus sp*. ATCC 8456   Wild type                                                                                                                        ATCC
  Plasmids                                                                                                                                                           
  pET28b                           Km^r^, T7 promoter, pBR322 origin                                                                                                Novagen
  pET28b-*oleT*~*JE*~              Km^r^, pET28b derivative containing *oleT*~*JE*~ gene                                                                            This study
  pET28b-*oleT*~*JE*~-*RhFRED*     Km^r^, pET28b derivative containing *oleT*~*JE*~ and *RhFRED* gene                                                               This study
  pACYCDuet-1                      Cm^r^, T7 promoter, P15A origin                                                                                                  Novagen
  pACYCDuet-*fdR*                  Cm^r^, pACYCDuet-1 derivative containing *fdR* gene                                                                              This study
  pCDFDuet-1                       Str^r^, T7 promoter, CloDF13 origin                                                                                              Novagen
  pCDEDuet-*fld*                   Str^r^, pCDFDuet-1 derivative containing *fld* gene                                                                              This study
  pMSD8                            Amp^r^, *P*~*T7*~: *accB*, *C*, *D*, *A,* pSC101 origin                                                                          \[[@B43]\]
  pMSD15                           Cm^r^, P~*BAD*~: *tesA,* p15a origin                                                                                             \[[@B43]\]

^a^The *fadD* gene encodes the acyl-CoA synthetase, which is the first enzyme involved in fatty acid degradation. ^b^pMSD8: the expression vector for *E. coli* acyl-CoA carboxylase. ^c^pMSD15: the plasmid used for overexpression of the *E. coli* thioesterase gene *tesA*. Amp, ampicillin; Cm, chloramphenicol; Km, kanamycin; Str, streptomycin.

As expected, all these engineered strains successfully accumulated multiple *α*-alkenes, including 1-tridecene, trideca-1,6-diene, 1-pentadecene, pentadecene-1,8-diene and heptadeca-1,10-diene (Figure [5](#F5){ref-type="fig"}A and Additional file [4](#S4){ref-type="supplementary-material"}: Figure S4), which correspond to the decarboxylation products of the 14:0, 14:1, 16:0, 16:1 and 18:1 fatty acids, respectively. This fatty acid composition is consistent with previous reports \[[@B43]\]. In all cases, the major alkene product was heptadeca-1,10-diene with the highest yield of 7.7 mg·l^-1^ in YL7. Since XL100/(pMSD8 + pMSD15) is able to produce more free fatty acids than XL100 \[[@B43]\], the total alkene titers of YL7 and YL8 were significantly greater than those of YL5 and YL6. Notably, expression of P450 decarboxylases did not significantly affect the cell growth of all strains (Additional file [5](#S5){ref-type="supplementary-material"}: Figure S5).

![**Production of*α*-alkenes by heterologous expression of OleT**~**JE**~**or OleT**~**JE**~**-RhFRED in fatty acid-overproducing*Escherichia coli*strains. (A)** Production of *α*-alkenes by OleT~JE~ and OleT~JE~-RhFRED in two fatty acid-overproducing *E. coli* strains. The line chart denotes the alkene productivity. **(B)** The *α*-alkene production and fatty acid conversion profiles of strain YL7 in the defined mineral medium. The histograms demonstrate the titer of each detected *α*-alkene titers. The line chart demonstrates the conversion ratio of corresponding fatty acids. FFA, free fatty acid.](1754-6834-7-28-5){#F5}

According to a previous report \[[@B44]\], H~2~O~2~ levels in growing *E. coli* are less than 20 nM, and 2 μM H~2~O~2~ could cause substantial growth inhibition. Therefore, the physiological concentration of H~2~O~2~ is far below the optimal H~2~O~2~ concentration (200 to 500 μM) \[[@B16]\] for supporting OleT~JE~ catalysis. Thus, we had predicted that OleT~JE~-RhFRED using endogenous NADPH, whose physiological concentration is around 120 μM \[[@B45]\], might catalyze the decarboxylation more efficiently than OleT~JE~ using H~2~O~2~ as a cofactor. Unexpectedly, the highest titer (11.8 mg·l^-1^) and productivity (4.5 mg·g dcw^-1^) of total alkenes was achieved by YL7 with OleT~JE~ instead of YL8 with OleT~JE~-RhFRED. This contradiction has led to a hypothesis that OleT~JE~ is able to employ the native redox system of *E. coli* to drive catalysis, such as P450~CLA~ and P450~BSβ~\[[@B41]\].

To test this hypothesis, we expressed and purified the *E. coli* Fld and FdR. In the *in vitro* reaction containing OleT~JE~, Fld, FdR and NADPH, myristic acid was substantially converted into 1-tridecene (Figure [3](#F3){ref-type="fig"}). Therefore, Fld and FdR probably better serve OleT~JE~ than the fused RhFRED *in vivo*, explaining why YL7 was a better alkene producer than YL8. However, the supportive role of H~2~O~2~ cannot be entirely neglected.

Inspired by these results, we attempted to enhance the level of dissolving dioxygen for improving OleT~JE~ catalysis during the cultivation of the best alkene producer, YL7, by applying a higher rotation rate of 250 rpm. Moreover, the defined mineral medium \[[@B14]\] containing 3% glucose was used to standardize the culture condition for the future metabolic engineering, and the culture time was extended to 40 h. Significantly, the total alkene titer of YL7 under these conditions was 97.6 mg·l^-1^ (Figure [5](#F5){ref-type="fig"}B), which is almost seven-fold higher than that in lysogeny broth (LB) medium at 220 rpm for 20 h (Figure [5](#F5){ref-type="fig"}A). The productivity of total alkenes was also improved from 4.5 mg·g dcw^-1^ (in LB over 20 h) to 24.9 mg·g dcw^-1^ (in the defined mineral medium over 40 h, data not shown). Again, heptadeca-1,10-diene was the major alkene product (41.4 mg·l^-1^). As control, the production of free fatty acids by the strain XL100/(pMSD8 + pMSD15) without OleT~JE~ expression was evaluated. Octadec-11-enoic acid was the most abundant fatty acid with a titer of 96.1 mg·l^-1^ (Additional file [6](#S6){ref-type="supplementary-material"}: Figure S6). This well explains why its decarboxylated product, heptadeca-1,10-diene, had the highest yield among produced alkenes (Figure [5](#F5){ref-type="fig"}). With respect to fatty acid conversion, octadec-11-enoic acid had the highest conversion ratio (85.9%) followed by hexadec-9-enoic acid (85.7%), myristic acid (75.7%), palmitic acid (74.0%) and lauric acid (24.4%). The low conversion of lauric acid seems to be inconsistent with the *in vitro* result (Figure [4](#F4){ref-type="fig"}A), which is likely due to the low intracellular concentration of the C~12~ fatty acid.

Discussion
==========

The cytochrome P450 enzymes are a superfamily of b-type heme proteins, capable of catalyzing more than 20 different types of reactions \[[@B25],[@B46],[@B47]\]. The H~2~O~2~-assisted decarboxylation of long-chain fatty acids catalyzed by P450 OleT~JE~ represents a novel activity of this highly versatile superfamily. This activity may be mechanistically similar to that of P450~Rm~ (CYP53B) from the yeast *Rhodotorula minuta*\[[@B48]\], which decarboxylates isovalerate to form isobutene.

According to protein sequence alignment (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3), OleT~JE~ belongs to the CYP152 peroxygenase family together with the well-studied P450~BSβ~ and P450~SPα~\[[@B28],[@B29]\], and other members. Functionally, these P450 peroxygenases were previously thought to have no ability of utilizing dioxygen to drive catalysis as typical P450 monooxygenases do \[[@B39]\]. However, we have unambiguously demonstrated that OleT~JE~ can perform H~2~O~2~-independent catalysis when partnering with the fused RhFRED reductase or the *E. coli* Fld/FdR system to transfer electrons from NADPH to the heme iron reactive center. This strongly suggests that OleT~JE~ can undergo the monooxygenase catalytic cycle to generate the highly reactive ferryl-oxo cation radical species (Compound I) for catalysis. In the well-accepted mechanism for dioxygen activation in P450 monooxygenases (Figure [6](#F6){ref-type="fig"}), two protons (and two electrons from NADPH) are required for generation of Compound I \[[@B27]\]. However, the conserved threonine and an acidic residue involved in proton delivery in normal P450 monooxygenases \[[@B34],[@B40]\] are replaced by Pro and Arg, respectively, which are absolutely conserved in OleT~JE~ and all other known CYP152 family members (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3). This strongly suggests an unknown proton transfer pathway. To elucidate this hypothetical pathway, we are currently seeking to solve the crystal structure of OleT~JE~.

![**Proposed two alternative catalytic mechanisms of OleT**~**JE**~**with (monooxygenase-like) or without (peroxygenase-like) redox systems.** The Arg^245^ is proposed to be required for substrate anchoring via the strong electrostatic interactions with the carboxyl group of fatty acid substrate. The supply of two protons in the putative monooxygenase catalytic cycle remains unclear. The dashed arrow indicates the peroxide shunt pathway.](1754-6834-7-28-6){#F6}

Evolutionarily, because the early Earth's environment probably had more H~2~O~2~ and peroxygenated organic chemicals than O~2~, P450 peroxygenases are presumed to have emerged ahead of P450 monooxygenases \[[@B38]\]. Thus, the ability of most P450 monooxygenases to use H~2~O~2~ as a surrogate for the O~2~/2e^-^/2H^+^ system (peroxide shunt pathway, Figure [6](#F6){ref-type="fig"}) could be understood as a remnant function inherited from their peroxygenase ancestors, whereas the OleT~JE~ P450 peroxygenase bearing the monooxygenase property might represent a transition species during the evolving process from peroxygenase to monooxygenase.

Under certain circumstances, such as *in vitro* synthetic reactions using purified P450s and application of P450 enzymes in laundry detergents, the peroxygenase activity supported by H~2~O~2~ is advantageous because expensive redox partner proteins and NAD(P)H are not needed \[[@B30],[@B31]\]. However, the peroxygenase nature is not a good feature if attempting to construct a biofuel-producing microorganism by taking advantage of the fatty acid decarboxylation activity of OleT~JE~. Essentially, the intracellular level of H~2~O~2~ cannot be increased to the concentration (10^1^ to 10^2^ μM range) required for efficiently supporting OleT~JE~ because at this level, H~2~O~2~ is toxic or fatal to all organisms including *E. coli*. Thus, that the activity of P450 OleT~JE~ can be supported by O~2~/redox partner(s)/NADPH besides H~2~O~2~ is a significant discovery because the former three factors are more viable targets for metabolic engineering \[[@B49]-[@B51]\]. Being aware of this, future metabolic engineering work aiming to improve the *in vivo* productivity of *α*-alkenes by OleT~JE~ probably should be directed to improvement of the intracellular level of dioxygen, redox partner protein(s) and/or NADPH. For example, among numerous metabolic strategies for *in vivo* up-regulation of NADPH \[[@B49]\], the NADPH regenerating system could be used for maintaining the high intracellular level of this reducing cofactor to better support the activity of OleT~JE~ and the overproduction of fatty acids \[[@B52],[@B53]\], both of which require a sufficient supply of NADPH.

In the mutant *E. coli* strains with up-regulated fatty acid biosynthesis (XL100 and XL100/(pMSD8 + pMSD15)), both OleT~JE~ and OleT~JE~-RhFRED were functional, therefore significantly converting fatty acids into *α*-alkenes. Consistent with the previous report \[[@B16]\], the common major product of four engineered alkene producers (YL5-8) turned out to be heptadeca-1,10-diene, but the second most abundant alkene varied (Figure [5](#F5){ref-type="fig"}A). This is likely because octadec-11-enoic acid (the precursor of heptadeca-1,10-diene) was the predominant component of the fatty acid pool of the tested strains (Additional file [6](#S6){ref-type="supplementary-material"}: Figure S6). However, there might be an additional reason that octadec-11-enoic acid is a preferred substrate *in vivo*. Interestingly, in previous studies \[[@B43],[@B54],[@B55]\], palmitic acid rather than octadec-11-enoic acid was the major component in the fatty acid pool of *E. coli*. This inconsistency could be due to different culture conditions.

After 20 h cultures of YL7 in LB medium, significant amounts of fatty acids remained unreacted with OleT~JE~ (Additional file [4](#S4){ref-type="supplementary-material"}: Figure S4). By contrast, the majority of fatty acids in YL7 were consumed by OleT~JE~ over the longer and more oxygenated cultivation in the defined mineral medium (Figure [5](#F5){ref-type="fig"}B). This suggests that, at the current stage, the yield of fatty acids might be the major limiting factor for further improvement of *α*-alkene titers. Thus, the overproduction of fatty acids needs to be significantly optimized prior to other engineering efforts on up-regulating the level of OleT~JE~, redox partners, O~2~ and NADPH.

In this report, the best bio-hydrocarbon-producing strain YL7 accumulated 97.6 mg·l^-1^ of total alkenes. This yield is comparable to or better than a majority of engineered alkane and alkene biosynthetic pathways with reported yields. These include the artificial alkane biosynthetic pathway in *E. coli* consisting of the carboxylic acid reductase from *Mycobacterium marinum* that catalyzes formation of fatty aldehydes directly from fatty acids, and the aldehyde decarbonylase from *Synechocystis* sp. PCC 6803 to produce alkanes (yield: approximately 2 mg·l^-1^) \[[@B56]\]; the hybrid system using the fatty acid reductase complex (LuxC, LuxE and LuxD) to provide fatty aldehyde as the substrate for downstream aldehyde decarbonylase to generate alkanes (yield: approximately 2 to 5 mg·l^-1^) \[[@B20]\]; and the ATP required decarboxylation of 3-hydroxy-3-methylbutyrate catalyzed by the R74H mutant of mevalonate diphosphate decarboxylase from *Saccharomyces cerevisiae* (productivity: 5,888 pmol·h^-1^·g cells^-1^) \[[@B57]\]. It is only lower than the 300 mg·l^-1^ of total alkane titer produced when the cyanobacterial pathway consisting of the acyl-ACP reductase Orf1594 from *Synechococcus elongates* PCC7942 and the aldehyde decarbonylase from *Nostoc punctiforme* PCC73102 was heterologously expressed in *E. coli*\[[@B14]\]. However, it is expected that more metabolic engineering efforts and optimization of fermentation will further increase the total alkene titers of the OleT~JE~/*E. coli* system, which is currently ongoing in our laboratory.

Conclusions
===========

The H~2~O~2~ independence of OleT~JE~ described in this work not only raises a number of fundamental questions regarding its monooxygenase-like mechanism, but also could direct future metabolic engineering work toward improvement of O~2~/redox partner(s)/NADPH for optimal activity of OleT~JE~*in vivo*. Considering its high conversion rate *in vitro* and H~2~O~2~-independent functionality *in vivo*, it is of great potential for engineering a hyper-producer of *α*-alkenes on the basis of OleT~JE~.

Methods
=======

Materials
---------

Fatty acid substrates, terminal alkene authentic standards, and derivatizing reagents were purchased from TCI (Shanghai, China). Antibiotics were obtained from SolarBio (Beijing, China). Other chemicals were from Sigma Aldrich (St. Louis, MO, USA) or Ameresco (Solon, OH, USA). Oligonucleotides were synthesized by Sangon Biotech (Shanghai, China), and their sequences are shown in Additional file [7](#S7){ref-type="supplementary-material"}: Table S1. The *Pfu* DNA polymerases and all restriction endonucleases were obtained from Fermentas (Vilnius, Lithuania) or Takara (Dalian, China). The kits used for molecular cloning were from OMEGA Bio-Tek (Jinan, China) or Promega (Madison, WI, USA). Protein purification used Qiagen Ni-NTA resin (Valencia, CA, USA), Millipore Amicon Ultra centrifugal fliters (Billerica, MA, USA) and PD-10 desalting columns from GE Healthcare (Piscataway, NJ, USA). Bovine liver catalase was purchased from Sigma Aldrich.

Molecular cloning
-----------------

Strains and plasmids constructed and used in this study are listed in Table [1](#T1){ref-type="table"}. The gene of *oleT*~*JE*~ was amplified from the genomic DNA of *Jeotgalicoccus* sp. ATCC 8456 using the primer pair of OleT-NdeI/OleT-*Hin*dIII (Table [1](#T1){ref-type="table"}). The gel-cleaned PCR fragment was double digested by *Nde*I and *Hin*dIII and subsequently ligated into the *Nde*I/*Hin*dIII pre-treated pET28b to afford pET28b-*oleT*~*JE*~ (Additional file [8](#S8){ref-type="supplementary-material"}: Figure S7A). For pET28b-*oleT*~*JE*~*-RhFRED*, the genes of *oleT*~*JE*~ and *RhFRED* were first fused by overlap extension PCR \[[@B58]\]. Briefly, the gene encoding RhFRED reductase was amplified from the previously constructed pET28b-*pikC*-*RhFRED*\[[@B59],[@B60]\] with a pair of primers including RhFRED-F and RhFRED-R. The *oleT*~*JE*~ gene was amplified from pET28b-*oleT*~*JE*~, using the primers OleT-F and OleT-RhFRED-OE. Then the two PCR fragments with overlap sequence were mixed, annealed, extended and finally amplified with the OleT-F/RhFRED-R primer pair, giving rise to the fused gene of *oleT*~*JE*~-*RhFRED*. This fusion product was digested by *Nde*I/*Hin*dIII and inserted into the *Nde*I/*Hin*dIII-digested pET28b to generate pET28b-*oleT*~*JE*~-*RhFRED* (Additional file [8](#S8){ref-type="supplementary-material"}: Figure S7B).

Using the genomic DNA of *E. coli* DH5α as template, the two genes encoding Fld and FdR were amplified with the primer pairs of Fld-BamHI-F/Fld-SalI-R and FdR-BamHI-F/FdR-SalI-R, respectively. Next, the *fld* and *fdR* genes were sub-cloned into pACYCDuet-1 and pCDFDuet-1 respectively, resulting in pACYCDuet-*fld* and pCDFDuet-*fdR*. All sub-cloned sequences were confirmed by DNA sequencing at Sangon Biotech, Shanghai.

Protein overexpression and purification
---------------------------------------

The *E. coli* BL21(DE3) cells carrying the recombinant expression vector were grown at 37°C for 16 to 20 h in LB medium containing certain selective antibiotics (50 μg·ml^-1^ kanamycin, 34 μg·ml^-1^ chloramphenicol, or 50 μg·ml^-1^ streptomycin), which were used to inoculate (1:100 ratio) Terrific Broth medium containing corresponding antibiotics, thiamine (1 mM), 10% glycerol and a rare salt solution \[[@B61]\]. Cells were grown at 37°C for 3 to 4 h until the optical density at 600 nm (OD~600~) reached 0.6 to 0.8, at which isopropyl-*β*-~D~-thiogalactopyranoside (IPTG, 0.2 mM as final concentration) and *δ*-aminolevulinic acid (0.5 mM, only for P450 expression) were added, followed by 18 h of cultivation at 18°C.

Protein purification was carried out as described elsewhere \[[@B61]\] with slight modifications. Specifically, the cell pellets harvested by centrifugation (5,000 × g, 4°C, 15 min) were stored at -80°C and melted at ambient temperature immediately before use. Then the cell pellets were resuspended in 40 ml of pre-chilled lysis buffer (pH 8.0, 50 mM NaH~2~PO~4~, 300 mM NaCl, 10% glycerol and 10 mM imidazole) through vortexing. Following a sonication step, the cell lysate was centrifuged at 12,000 × g for 30 min to remove the insoluble fraction. To the supernatant, 1 ml of Ni-NTA resin was added and gently mixed at 4°C for 1 h. The slurry was loaded onto an empty column, and washed with approximately 100 ml of wash buffer (pH 8.0, 50 mM NaH~2~PO~4~, 300 mM NaCl, 10% glycerol and 20 mM imidazole) until no proteins were detectable in flow-through. The bound target proteins were eluted with elution buffer (pH 8.0, 50 mM NaH~2~PO~4~, 300 mM NaCl, 10% glycerol and 250 mM imidazole). The eluent was concentrated with an Amicon Ultra centrifugal filter, and buffer exchanged on a PD-10 desalting column. Finally, the desalted purified proteins (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1) in storage buffer (pH 7.4, 50 mM NaH~2~PO~4~, 10% glycerol) were flash-frozen by liquid nitrogen and stored at -80°C for later use.

Determination of protein concentration
--------------------------------------

Following the method described by Omura and Sato \[[@B62]\], the CO-bound reduced difference spectrum (Additional file [2](#S2){ref-type="supplementary-material"}: Figure S2) of each P450 enzyme was recorded on a UV-visible spectrophotometer DU 800 (Beckman Coulter, Fullerton, CA, USA). The functional P450 concentration was calculated using the extinction coefficient (ϵ~450--490~) of 91,000 M^-1^·cm^-1^. The concentration of Fld and FdR from *E. coli* was determined using ϵ~579~ = 4,570 M^-1^·cm^-1^\[[@B63]\] and ϵ~456~ = 7,100 M^-1^·cm^-1^\[[@B64]\], respectively.

*In vitro* enzymatic assays with purified proteins
--------------------------------------------------

The fatty acid decarboxylation assays containing 0.2 to 1.0 μM OleT~JE~ or OleT~JE~-RhFRED, 200 μM fatty acid substrate (from C~8~ to C~20~), 500 μM H~2~O~2~ (for OleT~JE~) or 500 μM NADPH (for OleT~JE~-RhFRED) in 200 μl of storage buffer were carried out at 28°C for 2 h. In the assay to test whether *E. coli* Fld and FdR are able to support the activity of OleT~JE~, 5 μM Fld and 5 μM FdR were mixed with 200 μM myristic acid, 500 μM NADPH and 1 μM OleT~JE~ in 200 μl of storage buffer. To remove spontaneously generated H~2~O~2~, bovine liver catalase was added to the final concentration of 20 U·ml^-1^.

All above described reactions were quenched by addition of 20 μl of 10 M HCl. Heptadecanoic acid was added as internal standard and the mixture was extracted by 200 μl ethyl acetate. Samples were then analyzed by gas chromatography-mass spectroscopy (GC-MS; see below).

*In vivo* production of *α*-alkenes
-----------------------------------

The *E. coli fadD* deletion mutant strain XL100 \[[@B43]\] that overproduces fatty acids was selected as the starting host for construction of alkene-producing strains. Plasmids pMSD8 and pMSD15 were gifts from Dr. John Cronan and were used in the strain XL100 to construct fatty acid-overproducing strains. Bacterial cells transformed with certain plasmid(s) (Table [1](#T1){ref-type="table"}) were either grown in 50 ml of LB medium or in 50 ml of defined mineral medium \[[@B14]\] containing 3% glucose as the carbon source, supplemented with appropriate selective antibiotics, thiamine (1 mM) and a rare salt solution. All cultivations were performed at 37°C and induced at an OD~600~ of 0.9 to 1.0 with 0.4% arabinose (for pMSD15) followed by 0.2 mM IPTG (for pMSD8, and pET28b-*oleT*~*JE*~ or pET28b-*oleT*~*JE*~-*RhFRED*) after 0.5 h. Next, cells were grown at 28°C (the optimal temperature for OleT~JE~ expression) for an additional 20 h at 220 rpm (in LB medium) or 40 h at 250 rpm (in the defined mineral medium). For analysis of hydrocarbon production, 20 ml of culture with 10 μl heptadecanoic acid added as internal standard was sonicated for 10 min and then thoroughly mixed with an equal volume of chloroform-methanol (2:1, vol/vol). The aqueous-organic mixture was centrifuged (8,000 × g for 15 min) for phase separation. The organic phase was transferred into a clean tube, evaporated under a nitrogen flow, and re-dissolved in 500 μl of n-hexane as the testing sample. Prior to GC-MS analysis, 5 μl eicosane was added as calibration standard. All experiments were repeated two to four times.

Analytical methods
------------------

The GC-MS analytical method for hydrocarbon and fatty acid samples was adapted from Guan *et al.*\[[@B65]\]. The analyses were performed on an Agilent 7890A gas chromatograph equipped with a capillary column HP-INNOWAX (Agilent Technologies, Santa Clara, CA, USA; cross-linked polyethylene glycerol, i.d. 0.25 μm film thickness, 30 m by 0.25 mm) coupled to an Agilent 5975C MSD single quadrupole mass spectrometer operated under electron ionization mode at 70 eV in the scan range of 50 to 500 m/z. The helium flow rate was set to 1 ml·min^-1^. The oven temperature was controlled initially at 40°C for 4 min, then increased at the rate of 10°C per min to 250°C, and held for 15 min. The injecting temperature was set to 280°C with the injection volume of 1 μl under splitless injection conditions. Under these conditions, the previously reported thermal degradations of *α*- and *β*-hydroxy fatty acids to form alkenes (the minor products of OleT~JE~ catalyzed reaction) in the GC inlet \[[@B16]\] were not observed (Additional file [9](#S9){ref-type="supplementary-material"}: Figure S8), making the silylating protection of the hydroxyl group unnecessary if only caring about the *α*-alkene products. To detect *α*- and *β*-hydroxy fatty acids, samples were derivatized with an equal volume of *N, O*-bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane at 70°C for 15 min. GC-MS analysis followed the previous protocol developed by Rude *et al.*\[[@B16]\] except for using the Agilent J&W DB-5 MS column (i.d. 0.25 μm film thickness, 50 m by 0.25 mm). During GC-MS analysis, peak identity was determined by comparison of retention time and fragmentation pattern with authentic standard compounds where available and to the National Institute of Standards and Technology, USA mass spectral database. The location of double bond(s) in *α*-olefins was deduced by derivatization with dimethyl disulfide as described previously \[[@B66]\]. Quantification was achieved by comparison of integrated peak areas with calibration curves of authentic standards. The conversion percentages of free fatty acids to corresponding *α*-alkenes were estimated using the equation: \[total alkenes\]/(\[total alkenes\] + \[total free fatty acids\]).
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###### Additional file 1: Figure S1

SDS-PAGE analysis of purified **(A)** OleT~JE~ and **(B)** OleT~JE~-RhFRED. M, protein marker.
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###### Additional file 2: Figure S2

CO-bound reduced spectra of purified **(A)** OleT~JE~ and **(B)** OleT~JE~-RhFRED.
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###### Additional file 3: Figure S3

Protein sequence alignment of CYP152 family members and three selected P450 monooxygenases. Protein sequences were obtained from NCBI protein databases. CYP152A1 (P450~BSβ~ from *Bacillus subtilis*); CYP152A2 (P450~CLA~ from *Clostridium acetobutylicum*); CYP152B1 (P450~SPα~ from *Sphingomonas paucimobilis*); CYP152B2 (from *Azotobacter vinelandii*); CYP152C1 (from *Rhodobacter sphaeroides*); CYP152C2 (from *Rhodobacter sphaeroides*); CYP152D1 (from *Streptomyces scabies*); CYP152E1 (from *Cyanothece* sp. CCY0110); CYP107L1 (P450~PikC~ from *Streptomyces venezuelae*); CYP102A1 (P450~BM3~ from *Bacillus megaterium*); CYP101A1 (P450~cam~ from *Pseudomonas putida*). Conserved amino acid residues are shaded. The Arg and Pro absolutely conserved in CYP152 family are marked by asterisks.
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###### Additional file 4: Figure S4

GC-MS analysis of the organic extract of the YL7 culture in LB broth. Eicosane and heptadecanoic acid are served as calibration standard (CS) and internal standard (IS), respectively.
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###### Additional file 5: Figure S5

The dry cell weight of the YL5-8 cultures using LB broth.
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###### Additional file 6: Figure S6

Production profile of free fatty acids by the strain XL100/(pMSD8 + pMSD15).
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###### Additional file 7: Table S1

Primers used in this study.
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###### Additional file 8: Figure S7

Plasmid maps for **(A)** pET28b-*oleT*~*JE*~ and **(B)** pET28b-*oleT*~*JE*~-*RhFRED* expression vectors.
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###### Additional file 9: Figure S8

GC-MS analysis of the *α*- and *β*-hydroxy myristic acid authentic standards on HP-INNOWAX capillary column. **(A)** Without derivatization, *α*-hydroxy myristic acid was unseen due to its high boiling point. Importantly, no thermally degraded terminal olefin (1-tridecene) was observed in the dashed box. **(B)** Without derivatization, *β*-hydroxy myristic acid was unseen due to its high boiling point. Again, no thermally degraded terminal olefin (1-tridecene) was observed in the dashed box. **(C)** The decarboxylation reaction of myristic acid (2 h) catalyzed by OleT~JE~. The peak shown in the dashed box corresponds to 1-tridecene.
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